Acute Tumor Lysis Syndrome

Prevention and Management
  • Stuart L. Marcus
  • Avi I. Einzig

Abstract

Acute tumor lysis syndrome (ATLS) is a clinical entity that was first described in patients with either African or American Burkitt’s lymphoma who suffered sudden death within 2–3 days of treatment with chemotherapy.1 Initial observations suggested that hyperkalemia and renal failure occurring secondary to massive tumor lysis were responsible for patient demise. The syndrome associated with the treatment of tumors with very high rates of growth and rapid cell turnover is now expanded to include metabolic complications of hyperuricemia, hyperkalemia, and hyperphosphatemia with accompanying hypocalcemia (for recent reviews, see Cohen et al2 and Tsokos et al3) following chemotherapy. Certain of these complications, particularly hyperuricemia and renal failure, may also occur as the result of rapid cell turnover prior to treatment (see Section 2). This syndrome is almost exclusively associated with hematologic malignancies such as acute leukemia and malignant lymphoma, particularly Burkitt’s lymphoma (Table 1), diseases that have rapid cell proliferation but are also potentially curable, requiring aggressive treatment. ATLS in patients with solid tumors has been reported, however.5,9,10

Keywords

Acute Renal Failure Serum Uric Acid Serum Uric Acid Level Tumor Lysis Syndrome Serum Urate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arseneau JC, Bagley CM, Anderson T, Canellos GP: Hyperkalemia, a sequel to chemotherapy of Burkitt’s lymphoma. Lancet, Jan 6, 1973, pp 10–14.CrossRefGoogle Scholar
  2. 2.
    Cohen LF, Balow JE, MaGrath IT, Poplack DG, Ziegler JL: Acute tumor lysis syndrome: A review of 37 patients with Burkitt’s lymphoma. Am J Med 68: 486, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Tsokos GC, Balow JE, Spiegel RJ, MaGrath IT: Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 60: 218, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Fer MF, Bottino G, Sherwin SA, Hainsworth JD, Abrams PG, Foon KA, Oldham RA: Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Am J Med 77: 953, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Cech P, Block JB, Cone LA, Stome R.: Tumor lysis syndrome after tamoxifen flare. N Engl J Med 315: 263, 1986.PubMedCrossRefGoogle Scholar
  6. 6.
    Monballyu J, Zachee P, Verbeckmoes R, Boogaerts MA: Transient acute renal failure due to tumor lysis-induced severe phosphate load in a patient with Burkitt’s lymphoma. Clin Nephrol 22: 47, 1984.PubMedGoogle Scholar
  7. 7.
    Boles J-M, Dutel J-L, Brere J, Miazon P, Robasckiewicz M, Garre M, Briere J: Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53: 2425, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Boccia RV, Longo DL, Lieber ML, Jaffe ES, Fisher RI: Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkins lymphoma. Cancer 56: 2295, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Vogelzang NJ, Nelmark RA, Nath KA: Tumor lysis syndrome after induction chemotherapy of small-cell bronchogenic carcinoma. J Am Med Assoc 249: 513, 1983.CrossRefGoogle Scholar
  10. 10.
    Tomlinson GC, Solberg LA: Acute tumor lysis syndrome wtih metastatic medulloblastomaA case report. Cancer 53: 1783, 1984.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Stuart L. Marcus
    • 1
  • Avi I. Einzig
    • 2
  1. 1.Division of OncologyAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA
  2. 2.Division of OncologyAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA

Personalised recommendations